leadf
logo-loader
viewMotif Bio PLC

Motif Bio higher as it presents data from Phase III iclaprim trial

The presentation provided a drill-down in the results from the company’s REVIVE study

petrie dish
Motif also provided details of a recent lab-based data supporting iclaprim’s activity against Gram-positive bacteria collected from patients

Motif Bio PLC (LON:MTFB) (NASDAQ:MTFB) shares rose on Tuesday as the firm delivered new data on its lead drug, iclaprim, at the European Congress of Clinical Microbiology and Infectious Diseases, in Amsterdam.

The presentation provided a drill-down into the results from the company’s REVIVE Phase III study of people with skin and skin structure infections.

READ: Motif Bio receives vote of confidence as it raises £2.7mln

Among the headlines was an analysis by lesion size, which showed the antibiotic had comparable efficacy to vancomycin, the current standard of care.

Delegates heard the bacteremia rates were comparable between the two drugs, while the pharmacokinetics of iclaprim (the way the drug moves around the body) supported the use of a fixed dosing regimen.

Finally, Motif provided details of a recent lab-based data supporting iclaprim’s activity against Gram-positive bacteria collected from patients.

“Data are being presented that show that iclaprim continues to be active against a variety of antibiotic-resistant pathogens like methicillin-resistant (MRSA), methicillin-susceptible (MSSA) Staphylococcus aureus, and other Gram-positive skin and soft structure pathogens collected during 2017 from Europe and the US,” Motif said.

In early afternoon trading in London, Motif Bio shares were 4.9% higher at 8.82p.

 -- Adds share price --

Quick facts: Motif Bio PLC

Price: 0.5 GBX

AIM:MTFB
Market: AIM
Market Cap: £3.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Bam Bam Resources takes major step forward by increasing the size of Majuba...

Bam Bam Resources (CSE: BBR- OTC: NPEZF) CEO David Greenway shares news with Steve Darling from Proactive that the company has been able to increase its position on the Majuba Hill Project by 75%.   Greenway telling Proactive, the company added 168 new, unpatented lode mining claims...

3 hours, 10 minutes ago

2 min read